Vice President J.D. Vance didn't get the warmest of receptions at the Munich Security Conference when he entered into a speech attacking the governance of the European Union. According to Politico, ...

Klein-Baker's settlement agreement appears to be sealed. Simmons has been accused of sexual assault by at least a dozen women in recent years, including former Def Jam executive Drew Dixon.

It might sound to some like a small issue, but when free speech is not protected in a lawmaking body in Wales, that sets a dangerous precedent. My colleague Darren Millar was shut down in the Senedd ...

AKRON, OHIO / ACCESS Newswire / January 29, 2025 / ACU-Serve, a leader in healthcare revenue cycle optimization, is excited to announce the appointment of Sidney S. Simmons III (Sid) as its new ...

As Executive Vice President of Sales, Sid will oversee the company's dynamic sales team and lead initiatives to optimize and expand its sales operations. He is also being brought in to expand ...

Ben Simmons was once among the best players in the ... and it is without doubt the worst pain I've ever experienced It's also humiliating It's why I always will root for Simmons because I don ...

While the company's earnings beat was driven by its Innovative Medicines unit, mainly due to its multiple myeloma therapy, Darzalex, according to Bloomberg data on sales consensus, JNJ's MedTech ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

About 21 million U.S. adults in 2021 experienced at least one depressive episodes, latest government data shows. J&J said that about a third of adults will not respond to oral antidepressants alone.

Credit: Justin Paget via Getty Images. Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder ...

With an FDA nod on Tuesday, Johnson & Johnson’s esketamine nasal spray Spravato became the industry’s first monotherapy approved for use in adults with treatment-resistant depression. The approval ...